Work

Abstract ND03: Discovery of ARV-766, an androgen receptor degrading PROTAC® for the treatment of men with metastatic castration resistant prostate cancer

Year: 2023

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2023-nd03

Authors: Larry Snyder, S H. Lee, T K. Neklesa, X Chen, H Dong, C Ferraro, D A. Gordon, J Macaluso, J Pizzano, J Wang, R R. Willard, N Vitale, R Peck, M D. Moore, C M. Crews, J Houston, A P. Crew, I Taylor

Institutions: Arvinas (United States), Prelude Therapeutics Incorporated (United States)

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4380146458

Cites:

Cited by: 27

Related to: 10